Gain Therapeutics (GANX) Current Deferred Revenue (2020 - 2025)
Gain Therapeutics (GANX) posted quarterly Current Deferred Revenue of $11293.0 for Q3 2025, down 98.41% year-over-year from $708027.0 in Q3 2024, and down 50.22% quarter-over-quarter from $22685.0 in Q2 2025.
Gain Therapeutics (GANX) Current Deferred Revenue (2020 - 2025) Analysis & Trends
Gain Therapeutics' Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $11293.0 for Q3 2025.
- In Q3 2025, Current Deferred Revenue fell 98.41% year-over-year to $11293.0; the TTM figure through Sep 2025 stood at $11293.0 (down 98.41% YoY), while the FY2024 annual figure was $252211.0, down 77.52% from the prior year.
- Current Deferred Revenue for Q3 2025 stood at $11293.0, down from $22685.0 in the prior quarter.
- The five-year high for Current Deferred Revenue was $1.4 million in Q3 2023, with the low at $11293.0 in Q3 2025.
- The 5-year median for Current Deferred Revenue is $259357.5 (2021), against an average of $439851.4.
- The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue jumped 2352.96% in 2023, then slumped 98.41% in 2025.
- Gain Therapeutics' Current Deferred Revenue stood at $266504.0 in 2021, then sank by 79.29% to $55180.0 in 2022, then jumped by 1933.6% to $1.1 million in 2023, then plunged by 77.52% to $252211.0 in 2024, then slumped by 95.52% to $11293.0 in 2025.
- Business Quant data shows GANX's Current Deferred Revenue at $11293.0 in Q3 2025, $22685.0 in Q2 2025, and $217841.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 11,293.00 |
| Jun 30, 2025 | 22,685.00 |
| Mar 31, 2025 | 217,841.00 |
| Dec 31, 2024 | 252,211.00 |
| Sep 30, 2024 | 708,027.00 |
| Jun 30, 2024 | 710,001.00 |
| Mar 31, 2024 | 914,759.00 |
| Dec 31, 2023 | 1.12 Mn |
| Sep 30, 2023 | 1.35 Mn |
| Jun 30, 2023 | 1.07 Mn |
| Dec 31, 2022 | 55,180.00 |
| Sep 30, 2022 | 55,180.00 |
| Jun 30, 2022 | 80,198.00 |
| Mar 31, 2022 | 202,034.00 |
| Dec 31, 2021 | 266,504.00 |
| Sep 30, 2021 | 327,690.00 |
| Jun 30, 2021 | 370,518.00 |
| Mar 31, 2021 | 178,418.00 |
| Dec 31, 2020 | 239,483.00 |